It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.

Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services — such as connecting with living relatives with shared DNA — after its purchase closes as expected in the third quarter of this year.

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. | A federal jury in Delaware has determined that Amgen violated U.